{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:43:43Z","timestamp":1759970623058,"version":"build-2065373602"},"reference-count":55,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"Ministry of Science and ICT","doi-asserted-by":"publisher","award":["RS-2024-00441068","RS-2021-DD121165"],"award-info":[{"award-number":["RS-2024-00441068","RS-2021-DD121165"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004080","name":"Ministry of Science and ICT, the Ministry of Trade, Industry and Energy","doi-asserted-by":"publisher","award":["RS-2024-00441068","RS-2021-DD121165"],"award-info":[{"award-number":["RS-2024-00441068","RS-2021-DD121165"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Protein tyrosine kinase 7 (PTK7), a catalytically defective receptor protein tyrosine kinase, is frequently upregulated in various cancers, including triple-negative breast cancer (TNBC), and is associated with poor clinical outcomes. Analysis of The Cancer Genome Atlas (TCGA) data confirmed that PTK7 mRNA expression is significantly higher in TNBC tumor tissues compared with adjacent normal tissues and non-TNBC breast cancer subtypes. Kaplan\u2013Meier survival analysis demonstrated a strong correlation between high PTK7 expression and worse relapse-free survival in TNBC patients (HR = 1.46, p = 0.015). In vitro, anti-PTK7 monoclonal antibodies (mAbs) significantly reduced proliferation, wound healing, migration, and invasion in TNBC MDA-MB-231 cells. Ki-67 immunofluorescence assays revealed substantial decreases in cell proliferation following treatment with PTK7 mAbs (32-m, 43-m, 50-m, and 52-m). Moreover, actin polymerization, a critical process in cell migration and invasion, was markedly impaired upon PTK7 mAb treatment. In vivo, PTK7 mAbs significantly reduced tumor volume and weight in a TNBC xenograft mouse model compared with controls. Treated tumors exhibited decreased expression of Ki-67 and vimentin, indicating reduced proliferation and epithelial-to-mesenchymal transition. These findings highlight PTK7 as a promising therapeutic target in TNBC and demonstrate the potent anti-cancer effects of PTK7-neutralizing mAbs both in vitro and in vivo. Further exploration of PTK7-targeted therapies, including humanized mAbs and antibody-drug conjugates, is warranted to advance treatment strategies for PTK7-positive TNBC.<\/jats:p>","DOI":"10.3390\/cells14030181","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:26:31Z","timestamp":1737689191000},"page":"181","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-PTK7 Monoclonal Antibodies Suppresses Oncogenic Phenotypes in Cellular and Xenograft Models of Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"14","author":[{"given":"Min Ho","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4257-6799","authenticated-orcid":false,"given":"Mi Kyung","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Republic of Korea"},{"name":"Department of Biomedical Science, Hwasung Medi-Science University, Hwaseong 18274, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Na","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung Min","family":"Ham","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5573-742X","authenticated-orcid":false,"given":"Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang 10408, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7300-9784","authenticated-orcid":false,"given":"Seung-Taek","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/01.sla.0000245833.48399.9a","article-title":"Morbidity and mortality following breast cancer surgery in women: National benchmarks for standards of care","volume":"245","author":"Ward","year":"2007","journal-title":"Ann. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA. Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA. Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature17676","article-title":"Landscape of somatic mutations in 560 breast cancer whole-genome sequences","volume":"534","author":"Davies","year":"2016","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"eaag2611","DOI":"10.1126\/scitranslmed.aag2611","article-title":"A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions","volume":"9","author":"Damelin","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1200\/JCO.2012.46.1574","article-title":"Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from international breast cancer study group trials VIII and IX","volume":"31","author":"Sun","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2217\/fon.14.110","article-title":"Estrogen and progesterone receptors in breast cancer","volume":"10","author":"Yip","year":"2014","journal-title":"Future Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"dju296","DOI":"10.1093\/jnci\/dju296","article-title":"Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy","volume":"106","author":"Jordan","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Procter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103700","DOI":"10.1016\/j.esmoop.2024.103700","article-title":"Liquid biopsy in triple-negative breast cancer: Unlocking the potential of precision oncology","volume":"9","author":"Mazzeo","year":"2024","journal-title":"ESMO. Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ijo.2020.5135","article-title":"Triple-negative breast cancer therapy: Current and future perspectives (Review)","volume":"57","author":"Won","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/PPO.0000000000000497","article-title":"Immunotherapy in Triple-Negative Breast Cancer","volume":"27","author":"Emens","year":"2021","journal-title":"Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature02677","article-title":"PTK7\/CCK-4 is a novel regulator of planar cell polarity in vertebrates","volume":"430","author":"Lu","year":"2004","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1242\/dev.056291","article-title":"RACK1 is a novel interaction partner of PTK7 that is required for neural tube closure","volume":"138","author":"Wehner","year":"2011","journal-title":"Development"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"30562","DOI":"10.1074\/jbc.M115.697615","article-title":"The PTK7 and ROR2 Protein Receptors Interact in the Vertebrate WNT\/Planar Cell Polarity (PCP) Pathway","volume":"290","author":"Martinez","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.4161\/cc.10.8.15368","article-title":"PTK7: A cell polarity receptor with multiple facets","volume":"10","author":"Lhoumeau","year":"2011","journal-title":"Cell Cycle"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.abb.2011.12.019","article-title":"The many roles of PTK7: A versatile regulator of cell-cell communication","volume":"524","author":"Peradziryi","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/embor.2010.185","article-title":"Protein tyrosine kinase 7 has a conserved role in Wnt\/beta-catenin canonical signalling","volume":"12","author":"Puppo","year":"2011","journal-title":"EMBO. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1242\/dev.090183","article-title":"Ptk7 promotes non-canonical Wnt\/PCP-mediated morphogenesis and inhibits Wnt\/beta-catenin-dependent cell fate decisions during vertebrate development","volume":"140","author":"Hayes","year":"2013","journal-title":"Development"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41419-024-06713-7","article-title":"FOXP4-mediated induction of PTK7 activates the Wnt\/beta-catenin pathway and promotes ovarian cancer development","volume":"15","author":"Ji","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Shin, W.-S., Gim, J., Won, S., and Lee, S.-T. (2018). Biphasic regulation of tumorigenesis by PTK7 expression level in esophageal squamous cell carcinoma. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-26957-6"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Jin, Z., Guo, T., Zhang, X., Wang, X., and Liu, Y. (2024). PTK7: An underestimated contributor to human cancer. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1448695"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1016\/j.bbamcr.2015.05.015","article-title":"Biphasic effect of PTK7 on KDR activity in endothelial cells and angiogenesis","volume":"1853","author":"Shin","year":"2015","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Oh, S.W., Shin, W.S., and Lee, S.T. (2022). Anti-PTK7 Monoclonal Antibodies Inhibit Angiogenesis by Suppressing PTK7 Function. Cancers, 14.","DOI":"10.3390\/cancers14184463"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"73242","DOI":"10.18632\/oncotarget.12303","article-title":"Catalytically defective receptor protein tyrosine kinase PTK7 enhances invasive phenotype by inducing MMP-9 through activation of AP-1 and NF-kappaB in esophageal squamous cell carcinoma cells","volume":"7","author":"Shin","year":"2016","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12957-017-1172-x","article-title":"PTK7 is a novel oncogenic target for esophageal squamous cell carcinoma","volume":"15","author":"Liu","year":"2017","journal-title":"World J. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"12960","DOI":"10.1096\/fj.201900932R","article-title":"Catalytically inactive receptor tyrosine kinase PTK7 activates FGFR1 independent of FGF","volume":"33","author":"Shin","year":"2019","journal-title":"FASEB J."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Cui, N.P., Qiao, S., Jiang, S., Hu, J.L., Wang, T.T., Liu, W.W., Qin, Y., Wang, Y.N., Zheng, L.S., and Zhang, J.C. (2021). Protein Tyrosine Kinase 7 Regulates EGFR\/Akt Signaling Pathway and Correlates with Malignant Progression in Triple-Negative Breast Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.699889"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Shin, W.S., Oh, S.W., Park, H.N., Kim, J.H., and Lee, S.T. (2023). Knockdown of PTK7 Reduces the Oncogenic Potential of Breast Cancer Cells by Impeding Receptor Tyrosine Kinase Signaling. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241512173"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"G\u00e4rtner, S., Gunesch, A., Knyazeva, T., Wolf, P., H\u00f6gel, B., Eiermann, W., Ullrich, A., Knyazev, P., and Ataseven, B. (2014). PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0084472"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2147\/OTT.S62676","article-title":"PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs","volume":"7","author":"Ataseven","year":"2014","journal-title":"Onco. Targets Ther."},{"key":"ref_37","first-page":"3403","article-title":"A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes","volume":"8","author":"Lee","year":"1993","journal-title":"Oncogene"},{"key":"ref_38","first-page":"2179","article-title":"Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family","volume":"11","author":"Mossie","year":"1995","journal-title":"Oncogene"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/oxfordjournals.jbchem.a021228","article-title":"Characterization of the human full-length PTK7 cDNA encoding a receptor protein tyrosine kinase-like molecule closely related to chick KLG","volume":"119","author":"Park","year":"1996","journal-title":"J. Biochem."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kim, J.H., Shin, W.S., Lee, S.R., Kim, S., Choi, S.Y., and Lee, S.T. (2022). Anti-PTK7 Monoclonal Antibodies Exhibit Anti-Tumor Activity at the Cellular Level and in Mouse Xenograft Models of Esophageal Squamous Cell Carcinoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012195"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Lacey, K., Greener, M.R., Marak, T.R., Rakha, E.A., Green, A.R., Ellis, I.O., Martin, S.G., and Storr, S.J. (2024). Protein Tyrosine Kinase 7 (PTK7) in Breast Cancer: A Retrospective Analysis of Tumour Expression and Association with Clinical Outcome. Cancers, 16.","DOI":"10.3390\/cancers16183206"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"16458","DOI":"10.1021\/jacs.3c02752","article-title":"Cell Surface Labeling and Detection of Protein Tyrosine Kinase 7 via Covalent Aptamers","volume":"145","author":"Albright","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Shi, L., Li, J., Xiang, Q., Tan, Y., Zhang, H., Liu, S., Guo, X., Zhang, W., Yang, D., and Ma, Y. (2023). A dual-ratio fluorescent probe with a single excitation triple-signal to synchronously detect PTK7 and miRNA-21 for breast cancer early diagnosis. Biosens. Bioelectron., 237.","DOI":"10.1016\/j.bios.2023.115529"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/BF02616120","article-title":"Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization","volume":"14","author":"Cailleau","year":"1978","journal-title":"In Vitro"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2353\/ajpath.2007.061029","article-title":"Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth","volume":"171","author":"Urs","year":"2007","journal-title":"Am. J. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1016\/S0006-3495(96)79496-1","article-title":"Cell motility driven by actin polymerization","volume":"71","author":"Mogilner","year":"1996","journal-title":"Biophys. J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.bbamcr.2006.07.001","article-title":"Regulation of the actin cytoskeleton in cancer cell migration and invasion","volume":"1773","author":"Yamaguchi","year":"2007","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcancer.2007.08.001","article-title":"Reorganisation of the dendritic actin network during cancer cell migration and invasion","volume":"18","author":"Vignjevic","year":"2008","journal-title":"Semin. Cancer Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semcdb.2019.11.018","article-title":"Towards a structural understanding of the remodeling of the actin cytoskeleton","volume":"102","author":"Merino","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lucas, A.T., Moody, A., Schorzman, A.N., and Zamboni, W.C. (2021). Importance and Considerations of Antibody Engineering in Antibody-Drug Conjugates Development from a Clinical Pharmacologist\u2019s Perspective. Antibodies, 10.","DOI":"10.3390\/antib10030030"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Liu, X., Deng, J., Zhang, R., Xing, J., Wu, Y., Chen, W., Liang, B., Xing, D., Xu, J., and Zhang, M. (2023). The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1335252"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/1535-7163.MCT-23-0164","article-title":"MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors","volume":"22","author":"Kong","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kostova, V., Desos, P., Starck, J.B., and Kotschy, A. (2021). The Chemistry Behind ADCs. Pharmaceuticals, 14.","DOI":"10.3390\/ph14050442"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Garutti, M., Pelizzari, G., Bartoletti, M., Malfatti, M.C., Gerratana, L., Tell, G., and Puglisi, F. (2019). Platinum Salts in Patients with Breast Cancer: A Focus on Predictive Factors. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143390"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ctrv.2016.06.004","article-title":"Do platinum salts fit all triple negative breast cancers?","volume":"48","author":"Gerratana","year":"2016","journal-title":"Cancer Treat. Rev."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/3\/181\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:35:06Z","timestamp":1759919706000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/14\/3\/181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cells14030181"],"URL":"https:\/\/doi.org\/10.3390\/cells14030181","relation":{},"ISSN":["2073-4409"],"issn-type":[{"type":"electronic","value":"2073-4409"}],"subject":[],"published":{"date-parts":[[2025,1,24]]}}}